Literature DB >> 2069781

Mechanism of cyclosporine-induced hypertension.

R G Luke1.   

Abstract

Cyclosporine is a common immunosuppressive agent used in solid organ and bone marrow transplants and the treatment of some immunological diseases. It has been established that treatment with cyclosporine can cause a patient to develop hypertension within a few weeks of treatment. This review will examine this effect and effective ways to treat it.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2069781     DOI： 10.1093/ajh/4.5.468

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN： 0895-7061            Impact factor:   2.689


  12 in total

1.  Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.

Authors:  Dirk R Kuypers; Henrik Ekberg; Josep Grinyó; Björn Nashan; Flavio Vincenti; Paul Snell; Richard D Mamelok; Rene M Bouw
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

2.  Myeloid-Derived Suppressor Cells Ameliorate Cyclosporine A-Induced Hypertension in Mice.

Authors:  Valorie L Chiasson; Kelsey R Bounds; Piyali Chatterjee; Lochana Manandhar; Abhinandan R Pakanati; Marcos Hernandez; Bilal Aziz; Brett M Mitchell
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

Review 3.  Management of acute renal failure in the elderly. Treatment options.

Authors:  A K Mandal; M Baig; Z Koutoubi
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 4.  Cyclosporin-induced hypertension: incidence, pathogenesis and management.

Authors:  S J Taler; S C Textor; V J Canzanello; L Schwartz
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

5.  Is the beneficial effect of calcium channel blockers against cyclosporine A toxicity related to a restoration of ATP synthesis?

Authors:  M D Salducci; A M Chauvet-Monges; B M Dussol; Y F Berland; A D Crevat
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

Review 6.  Prevention and management of the adverse effects associated with immunosuppressive therapy.

Authors:  S J Rossi; T J Schroeder; S Hariharan; M R First
Journal:  Drug Saf       Date:  1993-08       Impact factor: 5.606

Review 7.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

Review 8.  Pathomechanisms and the diagnosis of arterial hypertension in pediatric renal allograft recipients.

Authors:  R Büscher; U Vester; A-M Wingen; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2004-11       Impact factor: 3.714

Review 9.  Role of hypertension in kidney transplant recipients.

Authors:  Charalampos Loutradis; Pantelis Sarafidis; Smaragdi Marinaki; Miriam Berry; Richard Borrows; Adnan Sharif; Charles J Ferro
Journal:  J Hum Hypertens       Date:  2021-05-04       Impact factor: 3.012

10.  HNF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension.

Authors:  Monika Niehof; Jürgen Borlak
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.